Idiopathic hyperprolactinemia-associated hypogonadism in men presenting with normal testosterone levels
PLOS One · 2025
DOI: 10.1371/journal.pone.0332871 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Xiaozhi Cheng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Andrology and Sexual Medicine, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China. Hauptthemen laut MEDLINE: Hyperprolactinemia, Testosterone, Hypogonadism. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Guangdong Medical Research Foundation.
Abstract (Originalsprache)
Purpose
Hypogonadism, presenting with low libido, erectile dysfunction, and gynecomastia, frequently occurs in men with hyperprolactinemia, typically characterized by elevated serum prolactin, suppressed gonadotropins, and low testosterone. However, we identified a rare subset of patients who presented with normal testosterone levels, but whose clinical profiles were poorly defined.
Methods
A retrospective analysis of medical records was conducted on 23 men diagnosed with idiopathic hyperprolactinemia and normal testosterone levels between 01/07/2019 and 01/12/2024. Baseline clinical characteristics, hormone levels, pituitary gland dimensions (as measured by MRI-derived pituitary height), and responses to medical treatments (bromocriptine or cabergoline) were evaluated.
Results
The mean age at diagnosis was 30.91 ± 7.66 years (range: 20–50). Mean serum prolactin at presentation was 38.22 ± 30.68 ng/mL (range: 20.00–170.93), and mean pituitary height was 6.40 ± 0.97 mm. Primary complaints at diagnosis included low libido, gynecomastia, impotence, and erectile dysfunction. Eighteen patients received bromocriptine, whereas five patients received cabergoline. After an average treatment duration of 7.83 ± 6.97 months (range: 1–29 months), prolactin levels normalized in all patients, pituitary height was significantly reduced to 4.39 ± 1.37 mm, and most patients reported notable clinical improvements, particularly in sexual function.
Conclusion
Idiopathic hyperprolactinemia-associated hypogonadism can occasionally present with normal testosterone levels, emphasizing the importance of clinical vigilance beyond standard hormonal assessments. Pituitary height reduction may serve as an important diagnostic marker and indicator of treatment effectiveness. Medical treatment, including bromocriptine or cabergoline, with a possible preference for cabergoline based on clinical considerations, can effectively normalize hormone levels and significantly improve clinical symptoms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Andrology and Sexual Medicine, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China.
- Department of Neurosurgery, People's Hospital of Gaozhou, Maoming, Guangdong, China.
- Department of Finance and Asset Management, People's Hospital of Gaozhou, Maoming, Guangdong, China.
ORCID-Profile: Xiaozhi Cheng
Förderung
- Guangdong Medical Research Foundation
Zitieren
APA
Cheng, X., Xiao, Y., Deng, Y., Chen, Q., Wen, X., Zhou, E., & Zhou, H. (2025). Idiopathic hyperprolactinemia-associated hypogonadism in men presenting with normal testosterone levels. PLOS One. https://doi.org/10.1371/journal.pone.0332871
Vancouver
Cheng X, Xiao Y, Deng Y, Chen Q, Wen X, Zhou E, et al. Idiopathic hyperprolactinemia-associated hypogonadism in men presenting with normal testosterone levels. PLOS One. 2025. doi:10.1371/journal.pone.0332871
BibTeX
@article{Cheng2025,
author = {Cheng, Xiaozhi and Xiao, Yunbei and Deng, Yulong and Chen, Qiwen and Wen, Xiaoyan and Zhou, Er and Zhou, Huiliang},
title = {Idiopathic hyperprolactinemia-associated hypogonadism in men presenting with normal testosterone levels},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0332871}
}
EUVIMED